1 Ocak 2022 Dergi makalesi Açık Erişim

Aksoy, Secil Ak; Tunca, Berrin; Ercelik, Melis; Tezcan, Gulcin; Ozturk, Ersin; Cecener, Gulsah; Ugras, Nesrin; Yilmazlar, Tuncay; Yerci, Omer

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/258999</identifier>
  <creators>
    <creator>
      <creatorName>Aksoy, Secil Ak</creatorName>
      <givenName>Secil Ak</givenName>
      <familyName>Aksoy</familyName>
      <affiliation>Uludag Univ, Vocat Sch Inegol, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Tunca, Berrin</creatorName>
      <givenName>Berrin</givenName>
      <familyName>Tunca</familyName>
      <affiliation>Uludag Univ, Med Fac, Dept Med Biol, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ercelik, Melis</creatorName>
      <givenName>Melis</givenName>
      <familyName>Ercelik</familyName>
      <affiliation>Uludag Univ, Med Fac, Dept Med Biol, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Tezcan, Gulcin</creatorName>
      <givenName>Gulcin</givenName>
      <familyName>Tezcan</familyName>
      <affiliation>Bursa Uludag Univ, Dept Fundamental Sci, Fac Dent, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ozturk, Ersin</creatorName>
      <givenName>Ersin</givenName>
      <familyName>Ozturk</familyName>
      <affiliation>Turkey Gen Surg, Dept Gen Surg, Med, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Cecener, Gulsah</creatorName>
      <givenName>Gulsah</givenName>
      <familyName>Cecener</familyName>
      <affiliation>Uludag Univ, Med Fac, Dept Med Biol, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ugras, Nesrin</creatorName>
      <givenName>Nesrin</givenName>
      <familyName>Ugras</familyName>
      <affiliation>Uludag Univ, Med Fac, Dept Pathol, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yilmazlar, Tuncay</creatorName>
      <givenName>Tuncay</givenName>
      <familyName>Yilmazlar</familyName>
      <affiliation>Uludag Univ, Med Fac, Dept Gen Surg, Bursa, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yerci, Omer</creatorName>
      <givenName>Omer</givenName>
      <familyName>Yerci</familyName>
      <affiliation>Uludag Univ, Med Fac, Dept Pathol, Bursa, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Early-Stage Colon Cancer With High Malat1 Expression Is Associated With The 5-Fluorouracil Resistance And Future Metastasis</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2022</publicationYear>
  <dates>
    <date dateType="Issued">2022-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/258999</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1007/s11033-022-07680-y</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Background This study aimed to investigate the role of long noncoding RNA (LncRNA) expression profiles to predict relapse and 5-FU response in patients with stage I/II colon cancer (CC). Methods and Results The expression level of 15 LncRNA was analyzed in stage I/II colon tumors of 126 CC patients. To confirm the findings in-vitro, 5FU-resistant HT29 cells were generated by subjecting HT-29 cells to the increasing concentrations of 5FU for 6 months. The 5FU resistance was observed in WST-1 and Annexin V analyses. The colony formation and wound healing assays were assessed to determine the metastatic properties of the cells. Expression levels of LncRNAs and mRNA of EMT-related genes were determined by RT-PCR. The role of LncRNA on metastasis and 5FU sensitivity were confirmed in pcDNA3.0-PTENP1 and si-MALAT1 expressed 5FU-resistant HT29 cell lineages. Results High MALAT1 (p = 0.0002) and low PTENP1 (p = 0.0044) expressions were significantly associated with 5-FU resistance and tumor relapse in stage I/II CC. The invasiveness and colony-forming characteristics of 5-FU-resistant cell lineages were higher as compared to the parent HT-29. Moreover, the expression of MALAT1 (p = 0.0009) was increased while the expression of PTENP1 (p = 0.0158) decreased in 5FU-resistant-HT-29 cells. Si-MALAT1 treatment increased cell sensitivity to 5FU, whereas it decreased invasive behaviors of 5 FU-resistant-HT-29 cells. Conclusion MALAT1 may be a biomarker in predicting recurrence in early-stage CC. Our findings suggest that a cell-based therapy to target MALAT1 could be established for these patients to prevent metastasis and 5-FU resistance.</description>
  </descriptions>
</resource>